Bristol Myers Squibb’s (BMY) Opdivo is part of the company’s alliance with Ono Pharmaceutical. Opdivo reported revenues of $1.2 billion during 2Q17, a rise of 42.0% compared to $840.0 million in 2Q16.

Performance of Bristol-Myers Squibb’s Opdivo in 2Q17

The above graph shows revenues for Opdivo over the last few quarters. Opdivo was the company’s largest revenue-contributing drug in 2Q17.

Uses of Opdivo

The blockbuster drug Opdivo is approved for the treatment of the following cancer patients:

  • previously treated patients with advanced non-small cell lung cancer
  • patients with metastatic melanoma
  • previously treated patients with advanced renal cell carcinoma
  • patients with squamous cell carcinoma of the head and neck that has relapsed or spread after previous treatments
  • patients with classical Hodgkin’s lymphoma where the disease has relapsed after an autologous stem cell transplant and treatment with Adcetris, or where the disease has relapsed after three or more treatments including autologous stem cell transplant
  • previously treated patients with advanced urothelial carcinoma
  • patients with metastatic, MSI-H (microsatellite instability high) or dMMR (DNA mismatch repair) colorectal cancer that has reported progression after treatment with fluoropyrimidine, irinotecan, and oxaliplatin

Recent Opdivo developments

Recent developments for Opdivo include the following:

  • On August 15, 2017, Bristol-Myers Squibb announced the results of its CheckMate 214 clinical study, a phase III study evaluating Opdivo in combination with Yervoy in poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.
  • On August 1, 2017, the FDA (U.S. Food & Drug Administration) approved Opdivo for the treatment of metastatic, MSI-H, or dMMR colorectal cancer in patients reporting disease progression after treatment with fluoropyrimidine, irinotecan, and oxaliplatin. The approval was based on the CheckMate 142 study.
  • On July 24, 2017, the FDA accepted the supplemental biologics application for updating the dosing of Opdivo 480 mg (milligram) to be infused over 30 minutes every four weeks for all approved monotherapy indications.

To divest the company-specific risks, investors can consider ETFs such as the Vanguard Healthcare ETF (VHT), which holds 2.8% of its total assets in Bristol-Myers Squibb (BMY). VHT also holds 4.9% in Merck & Co. (MRK), 3.3% in AbbVie (ABBV), and 2.8% in Gilead Sciences (GILD).

Latest articles

With the help of huge subsidies and favorable policies, the Chinese government seems to be determined to keep the electric vehicle revolution in the country alive.

On June 25, AbbVie (ABBV) announced that it plans to buy Allergan (AGN) for ~$63 billion. At 10:20 AM ET, Allergan stock rose 27%, while AbbVie stock fell 15%.

On June 25, Credit Suisse initiated its coverage on Shake Shack with an “outperform” rating and a target price of $77—an upside potential of 15.4% from its closing price of $66.72 on June 24.

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.